Tagrix 80 mg (Osimertinib)

Description

Tagrix 80 mg is the Bangladeshi version of osimertinib. It is formulated with the original formula. Original tagrisso and Bangladesh made Tagrix work the same. Not only that, Bangladeshi Tagrix costs about 70℅ less than the original Tagrisso but can deliver the same results. Tagrix-80 is manufactured by Beacon Pharmaceutical Limited.

 

Tagrix is the only first USFDA approved this kind of drug for the treatment of Non- Small Cell Lung Cancer patients.

 

FAQ About Tagrix 80

Q: What kind of drug is osimertinib?

Osimertinib belongs to the group of medicines called antineoplastic (cancer medicines). It works by interfering with the growth of cancer cells, which are eventually destroyed.

 

Q: Is Tagrix a form of chemotherapy?

No, Tagrix is not chemotherapy, but targeted therapy. Targeted therapies work differently than traditional chemotherapy. Chemotherapy kills rapidly dividing cells and can affect many types of cells in the body, including healthy cells.

 

Q: Is Tagrix a targeted therapy?

(Tagrix^®) is a targeted therapy drug. It is used to treat non-small cell lung cancer.

 

Q: How effective is Tagrix?

Tagrix 80 reduced the risk for disease recurrence or death by 79%). Tagrix was associated with superior DFS rates at 1 (97% vs 69%), 2 (89% vs 53%), and 3 years (79% vs 41%). The cancer drug (Tagrisso) improves survival in people with non-small cell lung cancer with EGFR mutations,

 

Q: Who invented this drug?

Tagrix (previously known as mereletinib or AZD9291, trade name Tagrisso) is a third-generation drug developed by AstraZeneca Pharmaceuticals for mutated EGFR cancers.

 

Q: What is the cost of this medicine?

In the U.S., this medicine cost $17,028.90 per month, compared erlotinib (Tarceva, Genentech) at $9,390.44, gefitinib (Iressa, AstraZeneca) at $9,117.36 and afatinib (Gilotrif, Boehringer Ingelheim) at $9,785.72. In the Bangladeshi version of tagrix Price is around $150 to $300 for 30 Tablets. before your order check our Terms & Condition

 

 

Use in Pregnancy & Lactation: Tagrix can cause fetal harm when administered to a pregnant woman. There are no available data on Tagrix use in pregnant women.

Lactation: There are no data on the presence of Tagrix in human milk. The effects of Tagrix on the breastfed infant, or milk production.

 

Overdose: If an overdose occurs the patient must be monitored for evidence of toxicity. Treatment of overdose includes monitoring of vital signs as well as observation of the clinical status of the patient.

 

Storage  Store in a cool and dry place, away from light. Keep out of the reach of children.